Editorial: Innovative strategies and new insights for the treatment of stage III non-small cell lung cancer

Front Oncol. 2024 Nov 4:14:1503613. doi: 10.3389/fonc.2024.1503613. eCollection 2024.

Francesco Cortiula^{1

2}, Aakash Desai³, Jessica Menis⁴, Andrea R Filippi^{5

6}

¹ Department of Oncology, University Hospital of Udine, Udine, Italy.
² Department of Radiation Oncology (Maastro), Maastricht University Medical Centre (+), GROW School for Oncology and Reproduction, Maastricht, Netherlands.
³ Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States.
⁴ Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust/Azienda Ospedaliero-Universitaria Integrata (AOUI), Verona, Italy.
⁵ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
⁶ Department of Radiotherapy, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

No abstract available

Keywords: biomarker; predictive model; radiation therapy; resectable NSCLC; stage III NSCLC.

Publication types